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Amiodarone HCl is an antiarrhythmic agent, which has low aqueous solubility and presents absorption 
problems. This study aimed to develop inclusion complexes containing hydrophilic carriers PEG 1500, 
4000 and 6000 by fusion and kneading methods in order to evaluate the increase in solubility and 
dissolution rate of amiodarone HCl. The solid dispersion and physical mixtures were characterized by 
X-ray diffraction, FT-IR spectra, water solubility and dissolution profiles. Both methods and carriers 
increased the solubility of drug, however PEG 6000 enhanced the drug solubility in solid dispersion 
better than other carriers. Different media were evaluated for the solubility study, including distilled 
water, acid buffer pH 1.2, acetate buffer pH 4.5 and phosphate buffer pH 6.8 at 37 ºC. Based on the 
evaluation of the results obtained in the study phase solubility carriers PEG 4000 and PEG 6000 were 
selected for the preparation of the physical mixture and solid dispersion. All formulations were prepared 
at drug-carrier ratios of 1:1 to 1:10(w/w). The results of in vitro release studies indicated that the solid 
dispersion technique by fusion method in proportion of 1:10 (w/w) increased significantly the dissolution 
rate of the drug. X-ray diffraction studies showed reduced drug crystallinity in the solid dispersions. 
FT-IR demonstrated interactions between the drug and polymers. 
Uniterms: Amiodarone hydrochloride/dissolution profile. Amiodarone hydrochloride/solid dispersion. 
Hydrophilic polymer. 
Cloridrato de amiodarona é um agente antiarrítmico que possui baixa solubilidade aquosa e apresenta 
problemas de absorção. Este estudo teve como objetivo desenvolver complexos de inclusão contendo 
carreadores hidrofílicos PEG 1500, 4000 e 6000 através dos métodos de fusão e amassamento para 
avaliar o aumento da solubilidade e taxa de dissolução do cloridrato de amiodarona. As dispersões sólidas 
e misturas físicas foram caracterizadas por difração de raios-X, espectroscopia no infravermelho com 
transformada de Fourier, solubilidade em água e perfis de dissolução. Ambos os métodos e carreadores 
aumentaram a solubilidade do fármaco, no entanto o PEG 6000 aumentou a solubilidade do fármaco 
na dispersão sólida mais que os outros carreadores. Diferentes meios foram avaliados para o estudo de 
solubilidade, incluindo água destilada, tampão ácido pH 1,2, tampão acetato pH 4,5 e tampão fosfato 
pH 6,8. Com base na avaliação dos resultados obtidos no estudo de solubilidade de fases, os carreadores 
PEG 4000 e PEG 6000 foram selecionados para a preparação das misturas físicas e dispersões sólidas. 
Todas as formulações foram preparadas nas razões fármaco-carreador de 1:1 a 1:10 (p/p). Os resultados 
de liberação in vitro que a técnica de dispersão sólida pelo método de fusão na proporção 1:10 (p/p) 
aumentou significativamente a taxa de dissolução do fármaco. Estudos de difração de raios-X mostraram 
redução da cristalinidade do fármaco na dispersão sólida. Análise por espectroscopia no infravermelho 
mostrou interações entre o fármaco e o carreador. 
Unitermos: Cloridrato de amiodarona/perfil de dissolução. Cloridrato de amiodarona/dispersão sólida. 
Polímero hidrofílico. 
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INTRODUCTION
Oral administration is the most common route for 
therapy of many diseases, however poorly soluble drugs 
have low bioavailability thereby decreasing treatment 
efficacy. For any active substance, aqueous solubility and 
intestinal permeability are key determinants that govern 
dissolution, absorption and oral bioavailability (Leuner, 
Dressman, 2000; Mutalik et al., 2008; Zisiou et al., 2005).
For certain drugs such as griseofulvin, indomethacin, 
chloramphenicol, carbamazepine, phenytoin, digoxin 
aqueous solubility is a challenge to researchers and 
the pharmaceutical industries (Badry, Fetih, Fathy, 
2009; Meshal et al., 1993). Hence, different studies are 
performed to increase the rate of dissolution of poorly 
water soluble drugs, to increase their effectiveness and 
simultaneously reduce their doses hence their toxic effects 
(Patel et al., 2008).
Generally the techniques of chemistry modification, 
micronization, micellar solubilization, pH adjustment, 
use of solid dispersion, and formation of the inclusion 
compounds such as cyclodextrin and derivatives, are 
utilized for enhanced solubility of drugs (Alves et al., 
2014; Chow et al., 1995; Flego, Lovrecich, Rubessa, 1988; 
Habib, Attia, 1985; Jablan, Szalontai, Jug, 2012; Vemula, 
Lagishetty, Lingala, 2010)
The solid dispersion technique was introduced 
in the early 1970s. Solid dispersion is one of the most 
successful strategies to improve the release of poorly 
soluble drug. This can be defined as dispersion of poorly 
water soluble drugs in hydrophilic carriers (Vasconcelos, 
Sarmento, Costa, 2007). The basic procedures used to 
prepare the solid dispersion are the fusion method, solvent 
evaporation method and hot extrusion method (Chiou, 
Riegelman, 1971; Modi, Tayade, 2006; Sammour et al., 
2006). Drug solubility is improved based on three different 
mechanisms: the increased wettability of the drug, the 
reduction of particle size and increased surface area, and 
the conversion of the crystalline state to the more soluble 
amorphous state (Lloyd, Craig, Smith, 1999; Taylor, 
Zografi, 1997; Waard et al., 2008).
AMH, chemically known as (2-butylbenzofuran-
3-yl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]
methanone hydrochloride, is a benzofuranic derivate, 
used for the treatment of both supraventricular and 
ventricular arrhythmias. AMH is a white or almost white, 
crystalline powder and is very slightly soluble in water 
(0.2–0.5 mg/mL), freely soluble in methylene chloride, 
soluble in methanol, sparingly soluble in ethanol (96 per 
cent) (British Pharmacopoeia, 2012; Eghrary et al., 2012; 
Riekes, et al., 2010; Index Merck, 2001; US Pharmacopeia, 
2012). AMH is classified as a class II drug based on the 
Biopharmaceutical Classification System (BCS), due to 
its low water solubility and high permeability (Riekes, et 
al., 2010). 
Few studies were shown in the literature about 
the improvement of aqueous solubility and absorption 
of AMH including Elhasi, Astaneh, Lavasanifar(2007); 
Jouyban, Eghrary, Zarghami (2013); Martín-Algarra et 
al.(1995); Paduraru et al. (2013) and Riekes et al. (2010).
The present study aimed to develop inclusion 
complexes containing hydrophilic carriers in order to 
evaluate increased AMH solubility and dissolution rate. 
The physicochemical characteristics and dissolution were 
assessed using Fourier transform infrared, X-ray powder 
diffraction and in vitro dissolution profiles. 
MATERIAL AND METHODS
Material
AMH with purity greater than 99.9% (standard 
substance) was obtained from Brazilian Pharmacopeia, 
batch 1040. The raw material AMH batch: 10104117A 
(purity > 99.0%) was purchased from Pharmanostra® 
(Brazil). Polyethylene glycol 1500 (PEG 1500), 4000 
(PEG 4000) e 6000 (PEG 6000) was purchased from 
Delaware® (Brazil). Water was prepared by ultra-pure 
water system (Milli-Q®). Other reagents and solvents used 
were of analytical grade.
Methods
Determination of AMH content
The AMH was quantified using the previously 
validated LC-method, employing a Shimadzu® (Kyoto, 
Japan), equipped with an LC-20AT pump, SIL-20A ht 
auto sampler, CTO-20AC column oven, SPD-M20A 
PDA detector, CBM-20A system controller, and LC 
solution software. The analyses were conducted using 
reverse phase Phenomenex® Luna C18 column (150 x 
4.6 mm, 5 µm). The mobile phase was composed of 
methanol:acetonitrile:buffer phosphate pH 2.2 (68:15:17), 
with a flow rate of 1.0 mL min-1, at 25.0 ºC and a volume 
of 10 µL was injected.
Solubility studies
This study was carried out to select a suitable 
dissolution medium for the in vitro drug release. An 
excess amount of AMH was transferred to an erlenmeyer, 
containing 10 mL of different solutions (distilled water, 
acid buffer pH 1.2, acetate buffer pH 4.5 and phosphate 
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buffer pH 6.8). Flasks were covered to avoid solvent loss 
and then shaken at 120 rpm in an orbital shaking incubator 
(Novatecnica®, NT712) for 24 hours at 37 ºC ± 0.5 ºC.
Phase solubility study
The phase solubility study was performed according 
to the method reported by Higuchi and Connors (1965). An 
excess amount of AMH was transferred to an Erlenmeyer 
flask containing 10 mL aqueous solutions with increasing 
concentrations of each carrier (i.e., 0.01, 0.05, 0.1, 0.3, 
0.5, 1.0, and 1.5%) (w/v). Flasks were covered to avoid 
solvent loss and then shaken at 120 rpm in an orbital 
shaking incubator (Novatecnica®, NT712) for 24 hours at 
25 and 37 ºC. After equilibrium, samples were centrifuged 
at 4000 rpm for 15 minutes and filtered through a 0.45 
µm membrane filter and analyzed for drug content using 
HPLC method. For determination of spontaneity of the 
dissolution process, the values of Gibbs free energy (ΔGtr) 
were calculated for each carrier in different temperatures 
in accordance with equation 1:
  (1)
w h e r e :  R  i s  t h e  u n i v e r s a l  g a s e s  c o n s t a n t 
(8.314472 J K-1 mol-1), T is the temperature in Kelvin, Sc 
is the solubility of the drug at a certain concentration of 
the carrier and So is the concentration of AMH in water in 
the absence of carrier, both in µg/mL
Preparation of solid dispersions and physical mixture
For the preparation of the physical mixture and solid 
dispersions using different methods, initially the drug and 
carrier were sieved at 355 µm mesh to standardize particle 
size and for storage in a desiccator. 
Physical mixtures (PM)
The PM of drug with carrier was prepared by mixing 
proportions 1:1 and 1:10 (w/w), respectively in a mortar 
for 10 min.
Solid dispersion by kneading method (SDKN)
The SDKN of drug with carrier was started from the 
PM, with subsequent kneading using water in a sufficient 
quantity to maintain a slightly moist consistency. After 20 
min of kneading, the mixture was left at room temperature 
for 24 hours and the product obtained was powdered in a 
mortar and passed through a 335 µm mesh. 
Solid dispersion by fusion method (SDFM)
The SDFM of drug in carrier was prepared as 
follows. The drug was added to the molten carrier at 
80 ºC with continuous stirring until the formation of a 
homogeneous dispersion. The dispersion was placed in 
a freezer at –80 ºC for 24 hours. After this period the 
product was ground using a mortar and passed through a 
355 µm mesh.
Characterization of the solid dispersions
Fourier transform infrared spectroscopy (FT-IR)
The samples were weighed about 5 mg and they 
were homogenized with 300 mg of potassium bromide 
using a mortar. The samples were then compressed using a 
hydraulic press to obtain a translucent tablet. The samples 
were scanned from (4000 to 450 cm-1) using a Perkin 
Elmer® spectrometer.
X-ray powder diffraction analysis (XRD)
The diffraction patterns of samples were obtained 
using an X-ray diffractometer (Rigaku®, Miniflex300), 
using Cu as an anode material, operated at a voltage of 
10 mA, 30 kV, monochromatic radiation (λ = 1.54051 Å). 
The samples were analyzed from 5º to 60º in the range of 
2θ, in increments of 0.03 º/s. 
In vitro dissolution profiles
Studies of dissolution of pure AMH, PMs and SDs 
with different carriers were performed in triplicate using 
dissolution test equipment, USP Apparatus 2 at 50 rpm 
with 900 mL dissolution medium (i.e. water, hydrochloric 
acid pH 1.2, buffer acetate pH 4.5 and buffer phosphate 
6.8) at 37 ºC ± 0.5 ºC. Samples of pure drug, PMs and 
SDs equivalent to 100 mg of the drug were utilized in 
evaluation. Dissolution studies were conducted for 90 
minutes, and 10 mL were collected at 5, 10, 15, 30, 60 
and 90 min intervals and replaced with an equal volume 
of fresh medium to maintain a constant total volume. The 
percentage of drug dissolved was determined using the 
HPLC method. 
RESULTS AND DISCUSSION
Solubility studies
The effect of pH on AMH solubility was observed. 
This drug presented poorly solubility in pH similar to 
the intestine, whereas in more acidic pH the values were 
higher. The results found are shown in Table I.
After evaluation of this study it became clear that in 
media with a pH equal to or greater than pKa the drug (6.56 
± 0.06) the molecule remains in a unionized form reducing 
the solubility (Boury et al., 2001; The Index Merck, 2001). 
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According to results, an increase of drug solubility in 
media with pH between 4.5 and 5.5 became clear. For this 
reason, these media were selected for evaluation of AMH 
solubility in solid dispersion. The high solubility of the 
drug in water when compared with the other media may be 
due to the presence of anions dissolved in buffer solutions, 
insoluble complexes being formed with molecules of the 
drug. (Avdeef, 2007; Boury et al., 2001; Ravin, Shami, 
Rattie, 1975). 
Phase solubility study
The phase solubility curves of pure AMH in the 
presence of PEG 1500, 4000 and 6000 at 25 and 37 ºC 
are shown in Figure 1. The apparent solubility of AMH 
increased with increasing temperature and carrier 
concentrations. Using the highest carrier concentration, 
the aqueous solubility increased approximately 1.07, 1.31 
and 5.72-fold for PEG 1500, 4000 and 6000, respectively 
at 25 ºC and 1.25, 1.58 and 3.51-fold, respectively at 37 ºC 
compared to pure drug. The solubility found this study 
for AMH in water at 25 and 37 ºC was 0.2815 and 0.4808 
mg/mL, respectively, very similar to that reported in the 
TABLE I - Solubility values of AMH in different dissolution 
media at 37 ºC ± 0.5 ºC
Dissolution media % drug solubilitya
Water distilled pH 5.5 14.20 ± 0.5330
Acid buffer pH 1.2 0.1395 ± 0.018
Acetate buffer pH 4.5 1.154 ± 0.2152
Phosphate buffer pH 6.8 0.0409 ± 0.0167
a values are expressed as mean ± SD, n = 4.
FIGURE 1 - Phase solubility curves of AMH in aqueous solutions of (A) PEG 1500, (B) PEG 4000 and (C) PEG 6000 at 25 and 
37 ºC ± 0.5 ºC (n = 3).
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TABLE II - Parameters for phase solubility studies of AMH obtained with different carriers at 25 and 37 ºC ± 0.5 ºC
Temperatures
25 ºC 37 ºC
Carrier Slope Solubilitya ΔGbtr Slope Solubilitya ΔGbtr
PEG 1500 0.0041 0.3 ± 0.006 - 171.27 0.1102 0.6 ± 0.006 - 575.47
PEG 4000 0.051 0.37 ± 0.004 - 691.36 0.2449 0.76 ± 0.004 - 245.56
PEG 6000 0.8308 1.61 ± 0.006 - 4336.58 0.6434 1.69 ± 0.021 -1185.38
aValues of solubility in 1.5% (w/v) of carrier concentration, in mg/mL ± SD, n = 2; bGibbs energy free in J/mol.
FIGURE 2 - FT-IR of the AMH pure (A), PEG 6000 (B), physical mixture, kneading method and fusion method.
literature (Amidon et al., 1995; Eghrary et al., 2012).
Table II shows the slopes of the curves. The higher 
slope value is associated with enhancement of the 
solubility. The Gibbs free energy (ΔGtr) relating to the 
spontaneity of the process of drug dissolution in aqueous 
solutions containing different carriers is shown in Table II. 
Generally, the increase in solubility is directly associated 
with values of ΔGtr < 0 being proportional to the increased 
carrier concentration (Patel et al., 2008).
In accordance with the results, the most negative 
values of ΔGtr were found for carrier PEG 4000 and PEG 
6000 in higher concentrations. After evaluation of the 
results obtained carriers PEG 4000 and PEG 6000 were 
selected for the preparation of the PMs and SDs. All 
formulations were prepared in the drug-carrier proportion 
of 1:1 and 1:10 (w/w).
Solid state characterization study
FT-IR spectroscopy studies
Spectroscopy analysis was utilized for verification 
of nature of interactions between AMH and carrier PEG 
6000. According to Verheyen et al. (2002), hydrogen 
bonding could be expected from the hydroxyl groups of 
PEG 6000. In the case of the AMH spectrum, the peaks 
in the region between 2960 and 2800 cm-1 are assigned 
to aliphatic C-H, the absorption bands characteristic to 
tert-amine NH+ stretching are located in the 2700-2200 
cm-1 range, at 1558 cm-1 and 1529 cm-1 related to aromatic 
C=C ring stretching. The spectrum of pure AMH, PEG 
6000 and solid dispersions by fusion method are shown 
in Figure 2.
The intensity of peaks in 1477 and 1454 cm-1 for 
the aromatic C=C ring semi-circle, at 1284 cm-1 specific 
to the ketonic C=O binding, had a significant reduction 
in the spectrum of the solid dispersion by fusion method 
1:10 (w/w), moreover the bands between 2700-2200 
cm-1 disappear from spectrum of solid dispersion. The 
FT-IR spectrum indicates that there is interaction between 
solid dispersion compounds and that it is likely that the 
complexation process was performed at the tert-amine of 
the AMH molecule.
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XRD analysis
The solubility, dissolution rate and bioavailability 
of some drugs can be parameters that depend on the 
solid-state form of the particles as amorphous, crystalline 
or polymorphic. The crystal is an organized structure in 
relation to molecules and atoms; on the other hand, the 
amorphous form is characterized by a random, generally 
more soluble state (Markovich et al., 1997). 
The XRD pattern of pure drug, physical mixture and 
their solid dispersion using PEG 6000 as carrier are shown 
in Figure 3. The XRD pattern of pure AMH showed intense 
peaks of crystallinity and PEG 6000 exhibited distinct 
patterns with diffraction peaks. This characteristic was also 
observed in studies by Mandal et al. (2010) and Riekes et 
al. (2010), when the interaction between simvastatin and 
PEG 6000 and AMH and β-cyclodextrin, respectively, 
was evaluated.
PM and SDKM showed characteristic peaks of 
both drug and polymer indicating the presence of drug 
crystallinity in these samples. In solid dispersion by 
fusion method in a proportion of 1:10 (SDFM 1:10), the 
intensity of characteristic drug peaks decreased and some 
peaks were suppressed, thus indicating reduction of drug 
crystallinity.
In vitro dissolution profiles
For drugs with low gastrointestinal solubility and 
high permeability, in this case the AMH, oral drug release 
is a limiting step for bioavailability. According to some 
authors, by improving drug solubility it is possible to 
FIGURE 3 - X-ray diffraction patterns of AMH, physical mixture and solid dispersions.
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enhance their bioavailability and reduce side effects. This 
effect of increasing bioavailability is so great that the 
dose administered could be lowered (Leuner, Dressman, 
2000; Streubel, Siepmann, Bodmeier, 2006; Vasconcelos, 
Sarmento, Costa, 2007). Poorly water-soluble drugs 
exhibit an insufficient dissolution rate and potential 
bioavailability problems due to erratic and incomplete 
absorption from the gastrointestinal tract (Bankar, 
Mahatma, 2012; Chiou, Riegelman, 1971). 
The dissolution profiles of pure drug, physical 
mixture and solid dispersions in 1:1 and 1:10 ratios (w/w) 
using PEG 4000 and PEG 6000 in dissolution media such 
as water and acetate buffer pH 4.5 are shown in Figure 4 
and Figure 5, respectively.
FIGURE 4 - Drug release profiles of pure AMH, physical mixture and solid dispersions obtained from fusion and kneading methods 
using water as dissolution medium at 37 ºC ± 0.5 ºC and carrier PEG 4000 (A) and carrier PEG 6000 (B).
FIGURE 5 - Drug release profiles of pure AMH, physical mixture and solid dispersions obtained from fusion and kneading methods 
using acetate buffer pH 4.5 as dissolution medium at 37 ºC ± 0.5 ºC and carrier PEG 4000 (A) and carrier PEG 6000 (B).
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Using PEG 4000 for preparation of formulations 
by the kneading method in the drug carrier proportion of 
1:1 (w/w), the highest values of dissolution rate of AMH 
were 0.038 mg/mL and 0.034 mg/mL in water and acetate 
buffer pH 4.5, respectively. For preparation methods by 
fusion and physical mixture, the drug dissolution was 
similar for both media and proportions of drug-carrier 
evaluated. 
On the other hand, using PEG 6000 as carrier, 
the dissolution rate of AMH was greater and faster for 
formulation prepared by the fusion method in a 1:10 
(w/w) proportion of drug:carrier in both dissolution 
media. After evaluation of the dissolution rate between the 
media, the drug solubility was more relevant when acetate 
buffer pH 4.5 was utilized as a dissolution medium. The 
product prepared by the fusion method at a proportion of 
1:10 (w/w) presented approximately a 4.4 fold increased 
solubility in acetate buffer 4.5 when compared with 
pure drug, demonstrating that it is an important tool for 
increasing the solubility of many molecules in biological 
fluids. With solid dispersion it became clear that drug 
solubility was increased compared with pure drug. This 
is explained by the formation of amorphous particles (as 
indicated by XRD analysis results), reduction of particle 
size and consequently larger surface area in contact with 
medium (Leuner, Dressman, 2000). Solid dispersions are 
one of the most successful strategies to improve solubility 
of drugs with low gastrointestinal solubility, where this 
promotes a greater quantity of drug molecules dissolved 
and free to be absorbed in the intestinal mucosa as in the 
case of AMH. 
CONCLUSION
In this work, solid dispersions were prepared with 
AMH and PEG 1500, 4000 and 6000 with different weight 
rates and methods. In the solubility study, the AMH shows 
a good result in water and acetate buffer pH 4.5 when 
compared with other media tested. The apparent solubility 
of AMH increased with increasing temperature and carrier 
concentrations and a more negative value of Gibbs free 
energy was obtained with carrier PEG 6000. FTIR and 
XDR studies showed evidence of interaction between the 
drug and PEG 6000 carrier for formulation SDFM 1:10 
(w/w). Furthermore, this formulation showed significantly 
higher drug solubility compared with pure drug after in 
vitro dissolution studies. In conclusion, these results could 
be an indication that solid dispersion by the fusion method 
could be useful for the development of pharmaceutical 
products containing AMH.
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